Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis
Tóm tắt
The prognosis of patients with cholangiocarcinoma historically has been poor, even after surgical resection. Although data from some single-institution series indicate improvement over historical results, survival after surgical therapy for cholangiocarcinoma has not been investigated in a population-based study. We used the Surveillance, Epidemiology, and End Results database to identify patients who underwent surgery for cholangiocarcinoma from 1973 through 2002. Multivariate modeling of survival after surgery for intrahepatic cholangiocarcinoma showed an improvement in survival only within the last decade studied, resulting in a cumulative 34.4% improvement in survival from 1992 through 2002. In contrast, multivariate modeling of survival after surgery for extrahepatic cholangiocarcinoma revealed a 23.3% increase in adjusted survival per each decade studied, resulting in a cumulative 53.7% improvement from 1973 through 2002. We conclude that survival after surgery for extrahepatic cholangiocarcinoma has dramatically improved since 1973. Patients with intrahepatic cholangiocarcinoma, however, have achieved an improvement in survival largely confined to more recent years. We suggest that these trends are largely caused by developments in imaging technology, improvements in patient selection, and advances in surgical techniques.
Tài liệu tham khảo
Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994;14:109–114.
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473; discussion 473–475.
Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115–125.
Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171–190.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303–1314.
Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.
Jan YY, Jeng LB, Hwang TL, Wang CS, Chen MF, Chen TJ. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 1996;43:614–619.
Casavilla FA, Marsh JW, Iwatsuki S, Todo S, Lee RG, Madariaga JR, Pinna A, Dvorchik I, Fung JJ, Starzl TE. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997;185:429–436.
Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: A 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41–47.
Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases. Ann Surg 1998;227:70–79.
Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou J, Belghiti J. Resection of intrahepatic cholangiocarcinoma: A western experience. J Hepatobiliary Pancreat Surg 1999;6:122–127.
Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505.
Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384–391.
Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.
Sugiura Y, Nakamura S, Iida S, Hosoda Y, Ikeuchi S, Mori S, Sugioka A, Tsuzuki T. Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: A cooperative study of the keio bile duct cancer study group. Surgery 1994;115:445–451.
Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P'eng FK. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384–394.
Nagino M, Nimura Y, Kamiya J, Kanai M, Uesaka K, Hayakawa N, Yamamoto H, Kondo S, Nishio H. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998;45:7–13.
Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, Kato A, Nakamura S, Omoto H, Nakajima N, Kimura F, Suwa T. Aggressive surgical approaches to hilar cholangiocarcinoma: Hepatic or local resection? Surgery 1998;123:131–136.
Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663–671.
Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808–818; discussion 819.
Bortolasi L, Burgart LJ, Tsiotos GG, Luque-De Leon E, Sarr MG. Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 2000;17:36–41.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–517; discussion 517–519.
Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73.
Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: Results of a prospective study. Ann Surg 2004;240:95–101.
Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, Larson D, Nagorney DM. Major hepatic resection for hilar cholangiocarcinoma: Analysis of 46 patients. Arch Surg 2004;139:514–523; discussion 523–525.
Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: The Nagoya experience. HPB 2005;7:259–262.
Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 2006;93:1488–1494.
National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, epidemiology, and end results (SEER) program (http://www.seer.cancer.gov) SEER*Stat database: Incidence, SEER 17 regs public-use, Nov 2005 sub (1973–2003 varying), linked to county attributes, total U.S., 1969–2003 counties. Released April 2006, based on the November 2005 submission.
Fritz AG. International Classification of Diseases for Oncology: ICD-O, 3rd ed. Geneva: World Health Organization, 2000.
Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the united states. J Natl Cancer Inst 2006;98:873–875.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941–948.
Cuzick J. A wilcoxon-type test for trend. Stat Med 1985;4:87–90.
Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187–220.
Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
Rubin DB, Schenker N. Multiple imputation in health-care databases: An overview and some applications. Stat Med 1991;10:585–598.
Schafer JL. Multiple imputation: A primer. Stat Methods Med Res 1999;8:3–15.
Royston P. Multiple imputation of missing values: Update of ICE. Stat J 2005;5:527–536.
Kooby DA, Jarnagin WR. Surgical management of hepatic malignancy. Cancer Invest 2004;22:283–303.
Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–15.
Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL. Perihilar cholangiocarcinoma. postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–797; discussion 797–798.
Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature. Eur J Cancer 1998;34:977–986.
Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(6):7–9.
Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945–951.
Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873–884; discussion 886–888, 893–895.